We develop clinic ready, analytically-validated biosimilar
cell lines, and manufacturing processes with proven
similarity to reference compounds.
32
21
7
We start every program with detailed patent discovery work, finding all valid and relevant patents in the US and EU.
We complete every aspect of analytical development for each program needed to characterize and control the biosimilar.
We screen biosimilar cell lines for each program, including single cell cloning, PQ screening, and production of a RCBs.
We develop end-to-end biosimilar processes from early upstream development through GMP drug substance production.
A New Kind of Biosimilar Partner
